Challenges and Opportunities for Typhoid Fever Control: A Call for Coordinated Action

Clinical Infectious Diseases

Volumn 62, Issue , 2016, Pages s4-s8

  Steele, A Duncan ^a   Hay Burgess, Deborah C ^a   Diaz, Zoey ^a   Carey, Megan E ^a   Zaidi, Anita K M ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Africa; enteric fever; MDR; typhoid conjugate vaccines; WSH

Indexed keywords

DRINKING WATER; TYPHOID VACCINE; TYPHOID PARATYPHOID VACCINE; VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; BONE MARROW CULTURE; ENVIRONMENTAL SANITATION; FOOD SAFETY; HEALTH CARE COST; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; MULTIDRUG RESISTANCE; NONHUMAN; PARATYPHOID FEVER; PERSONAL HYGIENE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALMONELLA ENTERICA SEROVAR PARATYPHI A; SALMONELLA ENTERICA SEROVAR TYPHI; TYPHOID FEVER; URBANIZATION; WATER QUALITY; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; DRUG EFFECTS; GLOBAL HEALTH; HEALTH SURVEY; INFANT; NEWBORN; PATHOGENICITY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; GLOBAL HEALTH; HUMANS; INFANT; INFANT, NEWBORN; PUBLIC HEALTH SURVEILLANCE; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84959918303     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ976     Document Type: Article

References (42)

1. Papagrigorakis MJ, Yapijakas C, Synodinos PN, Baziotopoulou-Valavani E. DNA examination of the ancient dental pulp incriminates typhoid fever as a probable cause of the plague of Athens. Int J Infect Dis 2006; 10:206-14.
2. McHugh J, Mackowiak PA. Death in the White House: President William Henry Harrison's atypical pneumonia. Clin Infect Dis 2014; 59:990-5.
3. Marineli F, Tsoucalas G, KaramanouM, Androutsos G. Mary Mallon (1869-1938) and the history of typhoid fever. Ann Gastroenterol 2013; 26:132-4.
4. Moorhead R. William Budd and typhoid fever. J R Soc Med 2002; 95:561-4.
5. Cirillo V. Arthur Conan Doyle (1859-1930): physician during the typhoid epidemic in the Anglo-Boer War (1899-1902). J Med Biography 2013; 22:2-8.
6. Mogasale V, Maskery B, Ochai RL, et al. Burden of typhoid fever in low-income and middle-income countries: A systematic, literature based update with risk factor adjustment. Lancet Glob Health 2014; 2:570-80.
7. Buckle GC, Fischer Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2012; 2:010401.
8. Global Burden of Disease 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117-71.
9. Ochai RL, Acosta CJ, Danovaro-Holliday MC, et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull WHO 2008; 86:260-8.
10. DeRoeck D, Ochai RL, Yang J, Anh DD, Alag V, Clemens JD. Typhoid vaccination: The Asian experience. Expert Rev Vaccines 2008; 7:547-60.
11. Arndt MB, Mosites EM, Tian M, et al. Estimating the burden of paratyphoid A in Asia and Africa. PLoS Negl Trop Dis 2014; 8:22925.
12. World Health Organization. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008; 83:49-60.
13. Marks F, Kalckreuth VV, Aaby P, et al. The incidence of invasive Salmonella disease in sub-Saharan Africa: A multi-centre population based surveillance study. Submitted.
14. Andrews JR,, Ryan ET. Diagnostics for invasive Salmonella infections: current challenges and future directions. Vaccine 2015; 33:C8-15.
15. World Health Organization. The diagnosis, treatment and prevention of typhoid fever. WHO/V&B/03. 17. Geneva, Switzerland: WHO, 2003.
16. Wain J, Diep TS, Bay PV, et al. Specimens and culture media for the laboratory diagnosis of typhoid fever. J Infect Dev Ctries 2008; 2:469-74.
17. Thriemer K, Ley B, Menten J, Jacobs J, van den Ende J. A systematic review and meta-analysis of the performance of two point of care typhoid fever tests, Tubex TF and Typhidot, in endemic countries. PLoS One 2013; 8:e81263.
18. Parry CM, Wijedoru L, Ariyal A, Baker S. The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev Anti Infect Ther 2011; 9:711-25.
19. Rahman BA, Wasfy MO, Maksoud MA, Hanna N, Dueger E, House B. Multi-drug resistance and reduced susceptibility to ciprofloxacin among Salmonella enterica serovar Typhi isolates from the Middle East and Central Asia. New Microbes New Infect 2014; 2:88-92.
20. Kariuki S, Gordon MA, Feasey NA, Parry CM. Antimicrobial resistance and management of invasive Salmonella disease. Vaccine 2015; 33(suppl 3):C21-9.
21. Hendriksen RS, Leekitcharoenphon P, Lukjancenko O, et al. Genomic signature of multidrug resistant Salmonella enterica serovar Typhi isolates related to a massive outbreak in Zambia between 2010 and 2012. J Clin Microbiol 2015; 53:262-72.
22. Parry CM. The treatment of multi-drug resistant and nalidixic acid resistant typhoid fever in Viet Nam. Trans Royal Soc Trop Med Hyg 2004; 83:413-22.
23. Feasey NA, Gaskell K, Wong V, et al. Rapid emergence of multidrug resistant H58-lineage Salmonella Typhi in Blantyre, Malawi. PLoS Negl Trop Dis 2015; 9: e0003748.
24. Hall RP, van Koppen B, van Houweling E. The human right to water: The importance of domestic and productive water rights. Sci Eng Ethics 2014; 20:849-68.
25. Cumming O, Elliot M, Overbo A, Bartram J. Does global progress on sanitation really lag behind water? An analysis of global progress on community and household level access to safe water and sanitation. PLoS One 2014; 9:e114699.
26. Hutton G. Global costs and benefits of reaching universal coverage of sanitation and drinking water supply. J Water Health 2013; 11:1-12.
27. Clasen T, Boisson S, Routray P, et al. Effectiveness of a rural sanitation programme on diarrhoea, soil-transmitted helminth infection and child malnutrition in Odisha, India: A cluster randomized trial. Lancet Glob Health 2014; 2: e645-53.
28. Patil SR, Arnold BF, Salvatore AL, et al. The effect of India's Total Sanitation Campaign on defecation behaviors and child health in rural Madhya Pradesh: A cluster randomized controlled trial. PLoS Med 2014; 11:e1001709.
29. Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: A cluster randomized openlabel trial. Lancet 2015; 386:1362-71.
30. Garmory HS, Brown KA, Titball KA. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002; 26:339-53.
31. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomized controlled field trial. Lancet 1990; 336:891-4.
32. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella Typhi live oral vaccine. Vaccine 1999; 17(suppl 2):S22-7.
33. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three or four doses of Ty21a live, oral typhoid vaccine in enteric-coated capsules: A field trial in an endemic area. J Infect Dis 1989; 159:766-9.
34. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella Typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14:435-8.
35. Keddy KH, Klugman KP, Hansford CF, Blondeau C, Le Cam NNB. Persistence of antibodies to Salmonella Typhi Vi capsular polysaccharide vaccine in South African school children after immunization. Vaccine 1999; 17:110-3.
36. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella Typhi. A preliminary report. N Engl J Med 1987; 317:1101-4.
37. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335-44.
38. Khan MI, Pach A, Khan GM, et al. Typhoid vaccine introduction: An evidence based pilot implementation project in Nepal and Pakistan. Vaccine 2015; 33 (suppl 3):C62-7.
39. Szu SC. Development of Vi conjugate. A new generation of typhoid vaccine. Exp Rev Vaccines 2013; 12:1273-86.
40. Lin FY, Ho Va, Khiem HB, et al. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9.
41. Bhutta ZA, Capeding MR, Bavdekar A, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children and infants in South and South-east Asia: results fromtwo randomized observer-blind, age deescalation, phase 2 trials. Lancet Infect Dis 2014; 14:119-29.
42. McGregor AC, Waddington CS, Pollard AJ. Prospects for prevention of Salmonella infection in children through vaccination. Curr Opin Infect Dis 2013; 26:254-62.